Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
Mariani P, Torossian N, van Laere S, Vermeulen P, de Koning L, Roman-Roman S, Lantz O, Rodrigues M, Stern MH, Gardrat S, Lesage L, Champenois G, Nicolas A, Matet A, Cassoux N, Servois V, Romano E, Piperno-Neumann S, Lugassy C, Barnhill R. Mariani P, et al. Among authors: torossian n. Br J Cancer. 2023 Sep;129(5):772-781. doi: 10.1038/s41416-023-02331-w. Epub 2023 Jul 13. Br J Cancer. 2023. PMID: 37443346
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
Vaflard P, Paoletti X, Servois V, Tresca P, Pons-Tostivint E, Sablin MP, Ricci F, Loirat D, Hescot S, Torossian N, Bello Roufai D, Kamal M, Borcoman E, Le Tourneau C. Vaflard P, et al. Among authors: torossian n. Drugs R D. 2021 Dec;21(4):399-406. doi: 10.1007/s40268-021-00362-3. Epub 2021 Sep 25. Drugs R D. 2021. PMID: 34562258 Free PMC article.
Advances in theranostic biomarkers for tumor immunotherapy.
Bellesoeur A, Torossian N, Amigorena S, Romano E. Bellesoeur A, et al. Among authors: torossian n. Curr Opin Chem Biol. 2020 Jun;56:79-90. doi: 10.1016/j.cbpa.2020.02.005. Epub 2020 Mar 24. Curr Opin Chem Biol. 2020. PMID: 32217357 Review.
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A, Masliah-Planchon J, Callens C, Vacher S, Lecerf C, Frelaut M, Borcoman E, Torossian N, Ricci F, Hescot S, Sablin MP, Tresca P, Loirat D, Melaabi S, Trabelsi-Grati O, Pierron G, Gentien D, Bernard V, Vincent Salomon A, Servant N, Bieche I, Le Tourneau C, Kamal M. Moreira A, et al. Among authors: torossian n. Eur J Cancer. 2019 Nov;121:202-209. doi: 10.1016/j.ejca.2019.09.001. Epub 2019 Oct 5. Eur J Cancer. 2019. PMID: 31593830